IMMUNEONCO-B
- Country
- 🇭🇰Hong Kong, China
- Ownership
- -
- Established
- 2015-06-18
- Employees
- 150
- Market Cap
- -
- Website
- http://cn.immuneonco.com
- Introduction
Yiming Angke Biomedical Technology (Shanghai) Co., Ltd. is a scientific research-oriented biotechnology company dedicated to developing innovative cancer immunotherapy. The company was incorporated in 2015 and is one of the few biotechnology companies in the world that can systematically utilize innate immunity and adaptive immune systems. By strictly adheri...
IMM40H Phase I Dose Escalation and Expansion
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05549557
Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05235438
- Locations
- 🇨🇳
Henan Cancer Hospital, Henan, China
🇨🇳Sun Yai-Sen Memorial Hospital,Sun Yai-Sen University, Guangzhou, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, China
A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT05140811
- Locations
- 🇨🇳
The first affiliated hospital of nanchang University, Nanchang, China
🇨🇳Shanghai sixth's hospital, Shanghai, China
🇨🇳Ganzhou People's Hospital, Ganzhou, China
IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT05076591
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Mary Crowley Cancer Research, Dallas, Texas, United States
🇺🇸NEXT Virginia, LLC, Fairfax, Virginia, United States
Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT04746131
- Locations
- 🇺🇸
The Christ Hospital, Cincinnati, Ohio, United States